Blue Goat Cyber
Medical Device Cybersecurity: Patient Safety, Market Access, and Regulatory Clearance Without Guesswork

Why has cybersecurity become a decisive factor in medical device regulatory clearance?

For years, medical device manufacturers could get a product through regulatory review with minimal cybersecurity evidence. Cybersecurity mattered, but it often wasn’t the deciding factor in whether a device could enter the market.

That has changed.

Today in the U.S., cybersecurity is mandated as part of FDA clearance. And globally, regulators are moving in the same direction. If you can’t demonstrate that you’ve designed cybersecurity into the product and validated it with defensible evidence, your submission can get delayed or rejected. When that happens, the impact includes lost revenue, burned runway, frustrated engineering teams, and often, a difficult conversation with investors about why the timeline just moved.

Christian Espinosa, Founder and CEO of Blue Goat Cyber, has seen companies get caught off guard by this shift. Sometimes they don’t take cybersecurity seriously until they watch a peer’s submission get rejected for missing or weak cybersecurity content. Other times, they assume it’s mostly about protecting data, and they miss what regulators are really evaluating: patient safety.

That’s where Blue Goat Cyber comes in. They treat cybersecurity as regulated infrastructure, and a key determination of whether a device reaches the market and whether clinicians can trust it once it’s deployed.

“We’re not looking at cybersecurity as a paperwork exercise,” says Espinosa. “It’s patient safety. If a device can’t be trusted in real clinical workflows, that’s not a technical issue. It’s a patient safety issue.”

Cybersecurity Isn’t Just Data Protection

Why does medical device cybersecurity extend far beyond protecting sensitive data?

One of the biggest misconceptions Espinosa still hears is that medical device cybersecurity is mainly about protecting sensitive data, such as patient health records, protected health information (PHI) and credit card numbers. Data protection matters, but when it comes to medical devices, it’s not the primary lens.

If someone can compromise an implanted defibrillator, a drug infusion pump or a surgical robot, the consequence isn’t a data breach. The consequence can be patient harm.

That’s why regulators are raising expectations, and why cybersecurity gaps are increasingly tied to recalls, not just compliance findings. The industry is starting to connect those dots, but it’s still not understood as widely as it should be.

Design It In, Don’t Bolt It On

Why must cybersecurity be integrated into device design rather than added late in development?

The second misconception is that cybersecurity can be added late, a few months before submission. That approach doesn’t work anymore, and honestly, it never really did.

Cybersecurity has to be designed into the product. The FDA expects it across the device lifecycle: from design through disposal. And it can’t be “one and done.” It has to be iterative; the same way you approach functional testing. You design, you validate, you test again, you improve, you validate again.

If a device can’t be trusted in real clinical workflows, that’s not a technical issue. It’s a patient safety issue.

“It’s much easier to design cybersecurity into a product than to bolt it on at the end,” Espinosa says. “Once core design choices are locked in, even small decisions can create downstream problems that delay clearance.”

If a manufacturer comes to them early enough, they can help them avoid painful rework later. Even a hardware decision, like selecting a microcontroller without the right security capabilities, can create major downstream issues once you’re heading toward submission. Fixing those problems late is what costs the most money and causes the most frustration.

What Clients Value Most: Experience, Speed, and Certainty

What do medical device manufacturers value most when engaging Blue Goat Cyber?

When manufacturers work with Blue Goat Cyber, they value a few consistent things.

First, the company understands exactly what they’re dealing with because they have done it at scale. They have completed more than 250 submissions for clearance or approval, know what regulators are looking for, how those expectations show up in practice, and how to produce evidence that holds up under review.

Second, they operate on a fixed-fee model. Their clients don’t have to worry about hourly overruns or open-ended consulting costs. If the team agrees on a scope and a fee, that’s what the client pays. Period. That makes budgeting predictable and reduces financial risk.

Third, they move fast. They have a dialed-in process, a dedicated team and project managers who keep things organized. If a company signs with them today, they can start tomorrow. That matters when a team is racing toward submission timelines.

And finally, they guarantee clearance from a cybersecurity perspective for the scope they support. If the FDA or another regulator comes back with questions or requests for additional information, they respond at no additional cost. They stay with the client until the device gets cleared, because that’s the outcome that matters.

“We guarantee clearance for the cybersecurity section,” Espinosa says. “If regulators ask for more information, we address it at no additional cost. We become a partner until the device is on the market, and then we support post-market monitoring too.”

Manual Testing Where Tools Stop

Why does manual testing remain essential in medical device cybersecurity validation?

Automation has value. Scanners can identify known vulnerability patterns quickly. But automated testing doesn’t understand clinical workflow. It doesn’t understand how the device is actually used by a nurse, a physician or a surgeon under time pressure. And it doesn’t understand downstream impact when device outputs are wrong, inconsistent, or manipulated.

Manual business logic testing means we evaluate how the device behaves in real use cases. Where are the inputs coming from? How does data flow through the system? What happens if something is modified upstream? How could that affect what a clinician sees and what they do next?

If a device starts producing sporadically inaccurate results, a clinician may stop trusting it. Then what? Now they’re reaching for an alternative device. Now they’re doing manual checks. Now the workflow slows down. And in systems where clinicians only have so much time per patient, that affects the quality of care.

Automated tools also create noise: false positives that waste engineering time. The team does the manual analysis required to filter out what doesn’t matter and focus teams on what actually improves safety and strengthens the regulatory posture.

“The way I look at it is simple,” Espinosa says. “If we miss something and it impacts a patient’s care, that’s a big problem. Automated tools don’t give the accuracy you need when the stakes are patient safety.”

SBOM as a Living System, Not a Submission Artifact

How does Blue Goat Cyber treat the Software Bill of Materials as an operational security tool?

Software bills of materials (SBOMs) are now a major focus of regulatory review, but their real value goes beyond submission.

Medical devices rely heavily on third-party software components: authentication libraries, operating system packages and open-source modules. Those components come with vulnerability profiles that change over time. What looks low-risk today can become a critical risk tomorrow if an exploit becomes widely known and easy to execute.

Pre-market, Blue Goat Cyber establishes traceability and baseline the risk: identifying vulnerabilities that must be addressed before clearance. Post-market, they monitor the SBOM continuously, in real time, so manufacturers can respond quickly when risk profiles shift.

“What wasn’t risky today can become super risky tomorrow,” Espinosa says. “If an attacker finds an easy way to exploit a component and publishes it, the risk changes immediately. That’s why monitoring after clearance matters just as much as what you submit.”

This is how you turn SBOM into an operational control surface, not just a document that passes review, but a tool that supports real-world vulnerability response after the device is in the field.

Removing Guesswork from Market Access

How does Blue Goat Cyber help manufacturers remove uncertainty from regulatory approval?

Manufacturers don’t just need cybersecurity deliverables. They need certainty.

The measurable outcome Blue Goat Cyber delivers is straightforward: they guarantee the cybersecurity portion of clearance. They know what the FDA is looking for, they produce evidence aligned to those expectations, and they stay engaged through review. They have had no deficiencies. Occasionally, regulators have questions, and they respond for the client, quickly and without extra cost.

Beyond clearance, when teams engage early, we help them make design decisions that avoid rework and keep timelines intact. That reduces burn, reduces investor risk and reduces the chance of finding late-stage issues that force redesign.

A Personal Stake in Device Trust

For Espinosa, their work to protect patient safety is personal. A few years ago, he had life-threatening blood clots. An ultrasound device helped diagnose them. If that device had been unreliable, or recalled or produced false results, he might not have been here.

That’s why he cares so much about trust. Devices have to work as intended when clinicians and patients depend on them. And cybersecurity is part of what makes that trust possible.

“If it wasn’t for a medical device, I might not be here,” Espinosa says. “That’s why patient safety is real to me. And it’s also why I want to help manufacturers get to market, because MedTech can truly change lives.”

As an entrepreneur, he also understands what innovators are up against. Blue Goat is built to support other entrepreneurs and MedTech teams, helping them get devices to market safely, without guessing and without getting derailed late in the process.

Cybersecurity as Infrastructure for Market Access

Cybersecurity is not an optional add-on, and it’s not a last-minute checklist. It’s infrastructure.

If manufacturers treat it as an afterthought, they risk delays, rejections and costly rework. If they treat it as part of the product, where it’s designed in, validated iteratively and monitored after clearance, they gain control over timelines, budgets and trust.

Blue Goat Cyber operates at the intersection of patient safety and market access. They help manufacturers design, test, document and govern cybersecurity across the full device lifecycle, so that devices can get cleared, get to market, make an impact on patients’ lives and stay trusted long after launch.

Ready to navigate MedTech cybersecurity with confidence?

Contact the Blue Goat Cyber team and schedule a no-cost Discovery Session:

https://bluegoatcyber.com

Email Id: info@bluegoatcyber.com

Phone Number: 844-939-4628 (GOAT)